

**SAMORITA HOSPITAL LIMITED**  
**Third Quarter Financial Statements**

Dear Shareholders,


We are pleased to forward herewith the unaudited Financial Statements of the company for the third quarter ended 31st March, 2024 as per Bangladesh Securities and Exchange Commission's notification No. SEC/CMRRC/2008-183/Admin/03-34 dated September 27, 2009.

**Statement of Financial Position (Un-audited)**  
**As at 31st March , 2024 ( Figure in Taka "000")**

Particular	Notes	March,31 2024	June, 30 2023
<b>Assets</b>			
<b>Non-Current Assets</b>			
Property, Plant & Equipment(WDV)	3	1,100,852	979,864
Right of Use Assets	4	1,198	2,395
Investment in Associate	5	5,973	5,944
<b>Total Non-Current Assets</b>		<b>1,108,023</b>	<b>988,203</b>
<b>Current Assets:</b>			
Inventories	6	20,906	20,649
Trade Receivable	7	9,092	10,048
Advance, Deposits & Prepayments	8	8,639	13,137
Advance Income Tax	9	12,974	13,528
Cash & Cash Equivalents	10	67,135	44,366
<b>Total Current Assets</b>		<b>118,746</b>	<b>101,728</b>
<b>Total Assets</b>		<b>1,226,769</b>	<b>1,089,931</b>
<b>Equity and Liabilities</b>			
<b>Shareholders' Equity:</b>			
Share Capital	11	218,009	198,190
Retained Earnings	12	121,444	121,110
Revaluation Reserve	14	753,343	636,826
Dividend Equalisation Fund	13	2,955	2,955
<b>Total Equity</b>		<b>1,095,751</b>	<b>959,081</b>
<b>Non- Current Liabilities :</b>			
Deferred Tax Liabilities	15	48,873	43,051
Lease Liability	16.01	742	742
Long Term Loan	17	18,328	18,328
<b>Total Non- Current Liabilities</b>		<b>67,943</b>	<b>62,121</b>
<b>Current Liabilities :</b>			
Trade Payable	18	30,758	31,813
Long Term Loan (Current Portion)	19	8,000	21,445
Lease Liability (current portion)	16.01	579	1,814
Other Payable	20	2,113	960
Provision & Accruals	21	10,415	6,372
Provision for Income Taxes	22	9,952	5,352
Unclaimed Dividend	23	1,258	973
<b>Total Current Liabilities</b>		<b>63,075</b>	<b>68,729</b>
<b>Total Liabilities</b>		<b>131,018</b>	<b>130,850</b>
<b>Total Equity and Liabilities</b>		<b>1,226,769</b>	<b>1,089,931</b>

**Statement of Profit or Loss and Other Comprehensive Income (Un-audited)**  
**For the third quarter ended 31st March , 2024. ( Figure in Taka "000")**

	Notes	July, 2023 to March, 2024	July, 2022 to March, 2023	January, 2024 to March, 2024	January, 2023 to March, 2023
Revenue	25	296,722	253,371	88,985	82,458
Direct Expenses	26	(118,458)	(102,843)	(38,128)	(34,050)
<b>Gross Profit</b>		<b>178,264</b>	<b>150,528</b>	<b>50,857</b>	<b>48,408</b>
<b>Operating Expenses:</b>					
Administrative Expenses	27	(153,308)	(140,655)	(50,917)	(46,407)
<b>Profit from Operation</b>		<b>24,955</b>	<b>9,873</b>	<b>(60)</b>	<b>2,001</b>
Share of Profit/ (loss) of Associate	24	29	45	8	28
Financial Expenses	28	(2,756)	(3,627)	(871)	(1,086)
Non Operating Income	29	4,698	5,458	1,432	1,628
<b>Profit before contribution to WPPF</b>		<b>26,926</b>	<b>11,749</b>	<b>509</b>	<b>2,571</b>
Contribution to WPPF		(1,282)	(559)	(24)	(121)
<b>Profit Before Tax</b>		<b>25,644</b>	<b>11,189</b>	<b>486</b>	<b>2,449</b>
<b>Income Tax Expenses</b>					
Current Tax	30	7,251	2,540	580	425
Deferred Tax	15.01	(1,760)	(72)	(566)	38
<b>Profit after Tax</b>		<b>20,153</b>	<b>8,721</b>	<b>471</b>	<b>1,986</b>
<b>Total Comprehensive income</b>		<b>20,153</b>	<b>8,721</b>	<b>471</b>	<b>1,986</b>
<b>EPS</b>		<b>0.92</b>	<b>0.40</b>	<b>0.02</b>	<b>0.09</b>

  
C F O

  
Company Secretary

  
Managing Director

  
Director

  
Chairman

**Statement of Changes In Equity (Un-audited)**  
For the third quarter ended 31st March , 2024. ( Figure in Taka "000")

Particular	Share Capital	Retained Earning	Dividend Equalisation Fund	Revaluation Reserve	Total
<b>Balance as at July 01,2023</b>	198,190	121,110	2,955	636,826	959,081
Transferred to Dividend Equalisation Fund		-	-		-
Total Comprehensive income	-	20,153		-	20,153
Revaluation Surplus on land				124,099	124,099
Transferred to Share Capital	19,819	(19,819)			-
Transferred to deferred tax liabilities				(7,582)	(7,582)
<b>Balance as at March 31,2024</b>	<b>218,009</b>	<b>121,444</b>	<b>2,955</b>	<b>753,343</b>	<b>1,095,751</b>
<b>Balance as at July 01,2022</b>	188,752	140,203	2,919	636,826	968,700
Transferred to Dividend Equalisation Fund		-	-		-
Dividend		(9,438)			(9,438)
Transferred to Share Capital	9,438	(9,438)			-
Total Comprehensive income	-	8,721	-	-	8,721
<b>Balance as at March 31,2023</b>	<b>198,190</b>	<b>130,048</b>	<b>2,919</b>	<b>636,826</b>	<b>967,983</b>

**Statement of Cash Flows (Un-audited)**  
For the third quarter ended 31st March , 2024. ( Figure in Taka "000")

	March,31 2024	March,31 2023
<b>A. Cash flows from Operating Activities:</b>		
Cash Received from Customers	300,560	259,127
Cash Paid to Suppliers & Employees	(247,498)	(217,778)
<b>Cash generated from Operations:</b>	<b>53,062</b>	<b>41,349</b>
Income Tax Paid	(2,097)	(2,725)
<b>Net Cash from Operating Activities</b>	<b>50,965</b>	<b>38,624</b>
<b>B. Cash flows from Investing Activities</b>		
Purchase of Property, Plant & Equipment	(14,220)	(24,955)
Bank Interest	342	223
FDR interest	1,472	1,612
<b>Net Cash used in Investing Activities</b>	<b>(12,406)</b>	<b>(23,120)</b>
<b>C. Cash flows from Financing Activities</b>		
Bank Loan paid	(16,075)	(15,845)
<b>Dividend Paid</b>		(9,438)
Unclaimed Dividend	285	(210)
<b>Net Cash Used in Financing Activities</b>	<b>(15,790)</b>	<b>(25,493)</b>
<b>D. Net Cash Inflows / (outflows)</b>	<b>22,769</b>	<b>(9,989)</b>
<b>E. Opening Cash &amp; Bank Balance</b>	<b>44,366</b>	<b>69,462</b>
<b>F. Closing Cash &amp; Bank Balance</b>	<b>67,135</b>	<b>59,473</b>

**Additional information as per listing regulation:**

Particulars	March,31 2024	June,30 2023
Net Assets Value per Share (NAV)	50.26	43.99
	March,31 2024	March,31 2023
Earning Per Share(EPS)	0.92	0.40
Net Operating Cash Flow Per Share(NOCFPS)	2.34	1.77

**Reasons of deviation in financial parameters:**


**Operating results:**

Operating result in the reporting period has been significantly increased due to the following reasons, compared to previous corresponding period:

- Revenue has been increased by Tk. 4.34 crore.
- Cost of direct materials has been decreased by 0.67%.
- Administrative expenses has been decreased from 55.51% to 51.67% of revenue.


Net operating cash flow per share (NOCFPS) increased from Tk. 1.77 to Tk.2.34 due to cash receipts from customers have been increased by Tk.4.14 crore and cash paid to suppliers & employees have been increased by Tk.2.97 crore resulting a net increase in cash generated from operation by Tk.1.17 crore.

d. Net Assets value (NAV) per share increased by Tk. 6.27 due to revaluation gain on land and usual business activities of the company.

  
C F O

  
Company Secretary

  
Managing Director

  
Director

  
Chairman

"The details of the published third quarter financial statements can be available in the web-site of the company. The address of the web-site is [www.samoritahospital.org](http://www.samoritahospital.org) "

**1.00 Legal status and nature of the Company-Disclosure under IAS-1 "Presentation of Financial Statements".**

**1.01 Company Profile**

Samorita Hospital Limited started its business from 01 February 1984 under the name and style as "M/s. Samorita Nursing Home". Then it was a partnership concern and 14 October 1985 it was converted into a Private Limited Company under the name and style as Samorita Nursing Home Ltd. Subsequently its name and style was changed and renamed as Samorita Hospital (Pvt.) Limited on 17 January 1990. Again on 23 June 1996 it was converted into a Public Limited Company under the name and style as "Samorita Hospital Limited".

The company went for public issue of share in 1996 and its shares are listed with the Stock Exchanges of Bangladesh.

**1.02 Basis of preparation of Financial Statements:**

These interim Financial Statements should be read in conjunction with the financial statements for the year ended 30th June, 2023 as they provide an update to previously reported information.

The Accounting Policies used are consistent with those in the Annual Financial Statements. The Financial Statements have been prepared in accordance with the applicable International Financial Reporting Standards (IFRS). The Presentation of the interim Financial Statements is consistent with the Annual Financial Statements.

**1.03 Investment in associate Company:**

The Company's investment in associate company is accounted for in the financial statements using the Equity Method in accordance with IAS-28 "Investment in Associates".

**2.00 Specific Accounting Policies selected and applied for Significant Transactions and Events:**

**2.01 Accounting Convention (Measurement IASs)**

The financial statements have been prepared on a going concern basis under the historical cost convention in accordance with International Financial Reporting Standards (IFRSs) therefore, do not take into consideration the effect of inflation.

**2.02 Statement of compliance**

The financial statements have been prepared in accordance with the applicable International Financial Reporting Standards (IFRSs), and The Companies Act 1994 and Securities & Exchange Rules 2020.

**2.03 Reporting Currency and Level of Precision**

The financial statements are presented in Bangladeshi Taka (BDT) which is the functional currency of the company. The amounts in these financial statements have been rounded off to the nearest integer.

**2.04 Risk and Uncertainties for use of estimates in preparation of Financial Statements**

The preparation of Financial Statements in conformity with the International Financial Reporting Standards requires management to make estimates and assumptions that affects the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and revenue and expenses during the period reported. Actual result could differ from those estimates. Estimates are used for accounting certain items such as long term contract, provision for doubtful contracts, depreciation and amortization, Tax reserve and contingencies.

**2.05 Reporting Period**

The company's accounting year is July-June and this financial statements are prepared covering the period of nine months from 01 July 2023 to 31 March 2024.

**2.06 Comparative Information**

Comparative information has been disclosed in respect of the period in accordance with IAS-1: Presentation of Financial Statements, for all numeric information in the financial statements and also the narrative and descriptive information where it is relevant for understanding of the current period's financial statements.

**2.07 Recognition of Property, Plant & Equipment and Depreciation**

Property, plant & equipment are recognized if it is probable that future economic benefits associated with the assets will flow to the company and the cost of the assets can be reliably measured. All fixed assets are stated at cost or revaluation less accumulated depreciation as per IAS-16 "Property, Plant and Equipment". No depreciation is charged on land and land development. The cost of acquisition of an asset comprises its purchase price and any directly attributable cost of bringing the asset to its working condition for its intended use inclusive of inward freight, duties and non-refundable taxes. The cost and accumulated depreciation of depreciable assets retired or otherwise disposed of are subject to elimination from the assets and accumulated depreciation and any gain or loss on such disposal will reflect in operations for the period.

**2.08 Revaluation of Freehold Land**

Samorita Hospital Limited revalued the freehold land on 30th September, 2023 by Basu Banerjee Nath & Co. a Chartered Accountancy firm and the details of the revaluation of Freehold Land of the Company as under:

Area of Land (Decimal)	Cost	Revaluation gain (As per revaluation of the year 2013)	Book value as on 30th June,2022	Current value as per revaluation on 30th Sept, 2023.	Revaluation gain
28.66	30,182,041	664,617,959	694,800,000	706,357,727	11,557,727
3.60	33,079,000	-	33,079,000	62,021,477	28,942,477
6.80	32,367,190	-	32,367,190	115,965,682	83,598,492
<b>39.06</b>	<b>95,628,231</b>	<b>664,617,959</b>	<b>760,246,190</b>	<b>884,344,886</b>	<b>124,098,696</b>

The Board of Directors adopted the valuation report in its 203rd meeting held on October 28, 2023 unanimously.

**2.09 Inventories**

Inventories comprise various Medicine, Material for Pathology, X-Ray, OT, Cleaning Materials, Linens, Printing and Stationery, Materials for ECG and USG. They are stated at the lower of cost and net realizable value in accordance with IAS -2 "Inventories" after making due allowances for any obsolete or slow moving items.

## 2.10 Financial Instruments

### Financial Assets

#### Trade Receivable

Trade receivables are recognized and stated at original invoiced amounts and carried at anticipated realizable values.

#### Cash and Cash Equivalent

It includes cash in hand and cash at bank which were held and available for use by the company without any restriction and there was insignificant risk of change in value of these current assets.

## 2.11 Creditors and Accrued Expenses

Liabilities are recognized for amounts to be paid in future for goods and services received, whether or not billed by the supplier.

## 2.12 Taxation

Income tax expenses comprise current and deferred taxes. Income taxes are recognized in statement of profit or loss and other comprehensive income except to the extent that relates to items recognized directly in equity or in other comprehensive income. The Company is a publicly traded Company. As per the Income Tax Act 2023, provision for Tax has been made at the existing rate of 22.50% in respect of business income.

### Current Tax

Provision for current income tax has been made as per prescribed rate in the Finance Act, 2023 on the accounting profit made by the company after considering some of the add backs to income and disallowances of expenditure as per income tax laws in compliance with IAS-12: "Income Taxes".

### Deferred Tax

Deferred tax liabilities are the amount of income taxes payable in future periods in respect of taxable temporary differences. Deferred tax assets are the amount of income taxes recoverable in future periods in respect of deductible temporary differences. Deferred tax assets and liabilities are recognized for the future tax consequences of timing differences arising between the carrying values of assets, liabilities, income and expenditure and their respective tax bases. Deferred tax assets and liabilities are measured using tax rates and tax laws that have been enacted or substantially enacted at the balance sheet date. The impact on the account of changes in the deferred tax assets and liabilities has also been recognized in the statement of comprehensive income as per IAS-12: "Income Taxes".

## 2.13 Revenue Recognition

In accordance with the provisions of the IFRS-15: "Revenue from Contracts with Customers"; revenue from contracts with customers represents the amount that reflects the considerations to which entity expects to be entitled in exchange for goods supplied and service provided to customers during the year. Revenue from contracts with customers is recognized in the statement of profit or loss and other comprehensive income when the performance obligation (supply of promised goods and services) is satisfied. Performance obligation is satisfied at a point in time when customer obtains the control of goods and services. Revenue has been recognized at the time of invoice made for the services rendered by the company.

### Interest income

The interest income is recognized on accrual basis as agreed terms and conditions with the banks.

### Non operating income

Non operating income are recognized at the time of receive of money from other purpose than the normal course of business of the Company.

## 2.14 Earnings Per Share (EPS)

The Company calculates Earnings Per Share (EPS) in accordance with IAS -33 "Earnings Per Share". which has been shown on the face of the statement of comprehensive income. This has been calculated by dividing the basic earnings by the number of ordinary shares outstanding during the year.

## 2.15 Statement of Cash Flows

Statement of Cash Flows is prepared principally in accordance with IAS -7 "Statement of Cash Flows" and the cash flow from the operating activities have been presented under the direct method as prescribed by the Securities and Exchange Rules 1987 and considering the provision of Paragraph 19 of IAS -7 which provides that enterprise are encouraged to report "Cash Flow from the Operating Activities using the direct Method".

## 2.16 Additional information on Financial Statements:

### Compliance with International Financial Reporting Standards (IFRSs)

The financial statements have been prepared in compliance with requirements of IFRSs adopted by the Institute of Chartered Accountants of Bangladesh (ICAB).

## 2.17 Foreign Exchange Earned and Payment

During the period the Company has not earned or made payment any amount of foreign currency.

## 2.18 Provisions, Contingent Liabilities and Contingent Assets (IAS-37)

There are certain pending tax claims made against the Company, which will be settled through the legal process in due course. These are being vigorously defended by the company. The management has not considered it necessary at the reporting date to make provisions in the financial statements in respect of any of these claims.

Accounting Year	Assessment Year	Tax Declared	Assessment by Tribunal	Tax paid	Tax Liability/ Claimed Amount	Present Status
2012-2013	2013-2014	13,623,217	12,843,912	13,723,217	(879,305)	Case is Pending at High court
2013-2014	2014-2015	11,669,566	15,188,234	12,879,566	2,308,668	Case is Pending at High court
2014-2015	2015-2016	11,473,176	12,616,428	11,773,176	843,252	Case is Pending at Tribunal

2015-2016	2016-2017	10,372,742	12,904,058	11,482,742	1,421,316	Case is Pending at High court
2016-2017	2017-2018	13,918,465	14,450,494	14,433,465	17,029	Case is Pending at High court
2017-2018	2018-2019	8,675,427	8,893,836	9,747,897	(854,061)	As per Assesment order
2018-2019	2019-2020	11,453,108	-	11,453,108	-	Return Submitted Under Section 82BB
2019-2020	2020-2021	3,678,790	13,143,637	9,329,484	3,814,153	Case is Pending at 2nd appeal (Tribunal)
2020-2021	2021-2022	13,632,068	16,541,199	11,246,630	5,294,569	Preparations are underway for sub-mission of appeal (Tribunal)
2021-2022	2022-2023	5,154,507	-	6,287,425	(1,132,918)	Return Submitted but Assessment not yet done
2022-2023	2023-2024	2,650,892	-	2,837,024	(186,132)	Return not Submitted
<b>Total</b>		<b>106,301,958</b>	<b>106,581,798</b>	<b>115,193,734</b>	<b>10,646,571</b>	

### 2.19 Impairment of Assets (IAS-36)

No facts and circumstances indicate that the company's assets may be impaired. Hence, no evaluation of recoverability of assets was performed.

### 2.20 Employee Benefits (IAS-19)

The Company provides short term employee benefits to its eligible employees in the form of incentive which charged as revenue expenditure in the period to which the incentive relates.

### 2.21 Workers' Profit Participation and Welfare Fund:

The Company recognizes a provision for Workers' Profit Participation Fund @ 5% of net profit before Taxes in accordance with Bangladesh Labour Law 2006.

<b>As at March, 31 2024</b>	<b>As at June, 30 2023</b>
-------------------------------------	------------------------------------

Figure in Taka"000"

### 3. Property, Plant & Equipment:

#### **Cost/Revaluation:**

Land	884,346	760,247
Building	257,539	254,281
Equipments	175,342	171,170
Furniture & Fixture	29,791	29,562
Lift	21,405	17,355
Generator	7,630	7,630
Medical Oxygen System	30,078	30,078
Others	42,586	40,076
	<u>1,448,717</u>	<u>1,310,399</u>
Less: Accumulated Depreciation	347,865	330,535
Written Down Value	<u>1,100,852</u>	<u>979,864</u>

#### **4.Right of Use Assets**

Cost	4,790	4,790
Less: Amortisation	3,592	2,395
	<u>1,198</u>	<u>2,395</u>

#### **5. Investment in Associate:**

Opening Balance	5,944	5,829
Share of income / (loss) of Associate (note.24)	29	39
Prior year adjustment	-	76
	<u>5,973</u>	<u>5,944</u>

Share of income of Associate has been shown on the basis of unaudited report of the Imaging services Ltd. (Associate company) for the 3rd quarter ended March 31, 2024 in accordance with IAS-28.

As at  
March, 31  
2024As at  
June, 30  
2023

Figure in Taka"000"

**6. Inventories:**

Medical Services	4,643	4,725
Diagnostics	5,320	3,806
Pharmacy	10,943	12,118
	<b>20,906</b>	<b>20,649</b>

**7. Trade Receivable:**

Receivable from Indoor Patient	5,390	6,003
Receivable from Outdoor Patient	886	698
Receivable from Institution	2,621	2,890
Rent Receivable	195	190
Receivable from FDR Interest	-	267
	<b>9,092</b>	<b>10,048</b>

**8. Advance, Deposits & Prepayments :**

Advance for Work & others	2,802	3,216
Advance for Capital Item	3,000	3,000
Security Money & Deposit	1,538	1,538
Prepayments	1,299	5,383
	<b>8,639</b>	<b>13,137</b>

**9. Advance Income Tax**

Opening Balance	13,528	15,788
Add: Paid during the year	2,097	2,895
	15,625	18,683
Less: Adjusted during the year	2,651	5,155
<b>Closing Balance</b>	<b>12,974</b>	<b>13,528</b>

**10. Cash & Cash Equivalents :**

Cash in hand	752	1,658
Union Bank FDR	2,587	20,000
Cash at bank	63,796	22,708
	<b>67,135</b>	<b>44,366</b>

**11. Issued, Subscribed and Paid up Capital:**

2,18,00,897 shares @ Tk. 10.00 each	<b>218,009</b>	<b>198,190</b>
-------------------------------------	----------------	----------------

**12. Retained Earnings**

Opening Balance	121,110	140,203
Less: Transfer to Share Capital	19,819	9,438
Less: Dividend Paid	-	9,438
Add: Prior year adjustment of Investment of Associate	-	76
Less: Prior Year Adjustment	-	978
	101,291	120,425
Add: Total Comprehensive Income for the year	20,153	721
	<b>121,444</b>	<b>121,146</b>
Less: Transferred to Dividend Equalisation Fund	-	36
	<b>121,444</b>	<b>121,110</b>

**13. Dividend Equalisation Fund:**

Opening	2,955	2,919
Add: Addition	-	36
<b>Closing</b>	<b>2,955</b>	<b>2,955</b>

**14. Revaluation Reserve**

Opening Balance	636,826	636,826
Add: Revaluation gain of land	124,099	-
Less: Transferred to Deferred tax Liabilities (note 14.01)	7,582	-
	<b>753,343</b>	<b>636,826</b>

**14.01. Movement in deferred tax liability**

Closing Balance	35,374	27,792
Opening Balance	27,792	27,792
	<b>7,582</b>	<b>-</b>

**15. Deferred Tax Liabilities**

Opening Balance	43,051	43,323
Add: Provision made during the year for temporary difference(Note:15.01)	(1,760)	(272)
Add: Transferred from Revaluation Reserve (note 14.01)	7,582	-
	<b>48,873</b>	<b>43,051</b>

**15.01 Deferred tax liability is arrived at as follows :****i. Deferred tax on PPE**

Carrying amount (Accounting base)	312,136	315,246
Carrying amount (Tax base)	250,968	247,427
Taxable/(deductible) temporary difference	61,168	67,819
Permanent differences	415	415
Net Taxable/(deductible) temporary difference	60,753	67,404
<b>Deferred tax Liability/(Assets) @ 22.50%</b>	<b>13,669</b>	<b>15,166</b>

	As at March, 31 2024	As at June, 30 2023
Figure in Taka"000"		
<b>ii. Deferred tax on Right of Use Assets</b>		
Carrying amount (Accounting base)	1,198	2,395
Carrying amount (Tax base)	-	-
Taxable/(deductible) temporary difference	1,198	2,395
<b>Deferred tax Liability/(Assets) @ 22.50%</b>	<b>270</b>	<b>539</b>
<b>iii. Deferred tax on Lease Liabilities</b>		
Carrying amount (Accounting base)	742	742
Carrying amount (Tax base)	-	-
Taxable/(deductible) temporary difference	(742)	(742)
<b>Deferred tax Liability/(Assets) @ 22.50%</b>	<b>(167)</b>	<b>(167)</b>
<b>iv. Deferred tax on share of profit on Investments</b>		
Carrying amount (Accounting base)	5,973	5,944
Carrying amount (Tax base)	7,335	7,335
Taxable/(deductible) temporary difference	(1,362)	(1,391)
<b>Deferred tax Liability/(Assets) @ 20%</b>	<b>(272)</b>	<b>(278)</b>
<b>v. Deferred tax on revaluation of property, plant and equipment:</b>		
Carrying amount (Accounting base)	884,345	694,800
Carrying amount (Tax base)	-	-
Taxable/(deductible) temporary difference	884,345	694,800
<b>Deferred tax Liability/(Assets) @ 4%</b>	<b>35,374</b>	<b>27,792</b>
<b>Total deferred tax liability as on Mar 31, 2024</b>	<b>48,873</b>	<b>43,052</b>
<b>Movement of Deferred Tax on PL Items</b>		
<b>Opening Deferred Tax Liability</b>	<b>15,260</b>	<b>15,531</b>
Expense/(Income) during the year	(1,760)	(271)
<b>Closing Deferred Tax Liability</b>	<b>13,500</b>	<b>15,260</b>
<b>16 Lease Liability</b>		
Opening Balance	2,556	4,079
Addition during the year	-	-
Finance costs during the year	126	292
Payments during the year	(1,361)	(1,815)
<b>Closing Liability</b>	<b>1,321</b>	<b>2,556</b>
<b>16.01 Lease Liability</b>		
Lease Liability-Current	579	1,814
Lease Liability-Non Current	742	742
	<b>1,321</b>	<b>2,556</b>
<b>17. Long Term Loan</b>		
<b>a. Principal Amount</b>		
Opening Balance	39,773	55,000
Add: Addition during the year	-	-
	<b>39,773</b>	55,000
Less: Repayment	13,445	15,227
<b>Total</b>	<b>26,328</b>	<b>39,773</b>
<b>b. Interest Amount</b>		
Opening Balance	-	1,551
Add: Addition during the year	2,630	4,332
	2,630	5,883
Less: Repayment	2,630	5,883
<b>Total</b>	<b>-</b>	<b>-</b>
<b>Closing Balance</b>	<b>26,328</b>	<b>39,773</b>
Less: Long Term Loan (Current Portion)	8,000	21,445
<b>Total</b>	<b>18,328</b>	<b>18,328</b>
<b>All fixed and floating assets are mortgaged against long term loan.</b>		
<b>18. Trade Payable:</b>		
Advance Receipt from Patient	1,161	1,076
Advance Receipt from MTB & Others	452	539
Current Liability for Expenses	737	733
Current Liabilities for Supply	13,153	15,493
Workers profit participation fund (note 18.01)	15,255	13,973
	<b>30,758</b>	<b>31,813</b>

As at  
March, 31  
2024

As at  
June, 30  
2023

Figure in Taka"000"

**18.01. Workers profit participation fund :**

Opening Balance	13,973	14,770
Less: Paid During the year	-	2,377
	13,973	12,393
Add: Provision made during the year	1,282	155
Add: Interest Charged for the year	-	1,425
	15,255	13,973

**19. Long Term Loan (Current Portion)**

Closing Balance	8,000	21,445
-----------------	-------	--------

**20. Other Payables**

Suppliers & Others Vat	935	514
Suppliers & Others Tax	910	446
Managing Directors Salary Tax	268	-
	2,113	960

**21. Provision & Accruals:**

Utility Bills	1,386	1,912
Salary & Allowance	8,799	4,156
Others	230	304
	10,415	6,372

**22. Provision for Income Taxes**

Opening Balance	5,352	7,856
Less: Adjusted during the year (Note-9)	2,651	5,155
	2,701	2,701
Less: Paid During the Year	-	-
	2,701	2,701
Add: Provision made during the year	7,251	2,651
	9,952	5,352

**23. Unclaimed Dividend**

Opening Balance	973	1,172
Add : Addition during the year	285	982
	1,258	2,154
Less: Capital Market Stabilization Fund	-	1,172
Less: Paid during the year	-	9
	1,258	973

The Above amount of Tk.973,000 has been unclaimed for the financial year 2020-2021. As per BSEC Directive No. BSEC/CMRRC/2021-386/03 dt.January 14, 2021 the amount shall be payable to CMFS as soon as the expiry of 3 years. Hence the amount shall be payable to CMSF on 29th December, 2024.

March, 31  
2024

March, 31  
2023

Figure in Taka"000"

**24. Share of Profit / (loss) of Associate :**

Net profit/ (loss) of Associate company	65	99
Share of Profit/ (loss) of Associate company (45% of Tk. 65 )	29	45

**25. Revenue**

Medical Services	137,412	111,064
Diagnostic	77,284	68,114
Pharmacy	82,026	74,193
	296,722	253,371

**26. Direct Expenses:**

Medical Services	25,759	22,024
Diagnostic	30,338	25,709
Pharmacy	62,361	55,110
	118,458	102,843



	March, 31 2024	March, 31 2023
Figure in Taka"000"		
<b>27. Administrative Expenses:</b>		
Salary & Allowance	82,619	76,691
Managing Director's Salary	6,201	6,177
Utility Bills	14,214	12,221
Repair	9,184	6,044
Depreciation	17,331	17,410
Depreciation on Right of Use Assets	1,198	1,198
Printing	1,685	1,527
Bad debt	1,546	272
Others	19,330	19,115
	<b>153,308</b>	<b>140,655</b>
<b>28. Financial Expenses</b>		
Interest on Term Loan	2,630	3,395
Interest on Lease Liability	126	232
	<b>2,756</b>	<b>3,627</b>
<b>29. Non Operating Income</b>		
Rent Received	2,390	2,530
FDR Interest	1,205	1,699
Bank Interest	342	223
Referral Income	491	327
Others	270	679
	<b>4,698</b>	<b>5,458</b>
<b>30. Current year's Tax</b>		
	<b>7,251</b>	<b>2,540</b>
<b>i. Regular Tax</b>		
Net profit before tax as per profit & loss Account	25,644	11,189
Less: Profit/(Loss) from Investments	29	45
	<b>25,614</b>	<b>11,145</b>
<b>Add: Items of charges to be considered separately:</b>		
Accounting depreciation	17,331	17,410
Depreciation on RoU Assets	1,198	1,198
Finance Cost on Lease Liabilities	126	232
	<b>18,655</b>	<b>18,840</b>
<b>Less: Admissible items:</b>		
Payments for Leases	1,361	1,361
Tax depreciation	10,680	17,334
	<b>12,041</b>	<b>18,695</b>
<b>Total business income during the year</b>	<b>32,228</b>	<b>11,290</b>
Regular Tax on business income @ 22.5%	7,251	2,540
	<b>7,251</b>	<b>2,540</b>

**31. Special disclosure as per notification No. BSEC/CMRRCD/2006-158/208/Admin/81 is as under:**

	As at March, 31 2024	As at June, 30 2023
Figure in Taka"000"		
<b>a) Detailed break-up of shareholders equity:</b>		
Share Capital (note- a.01)	218,009	198,190
Retained Earnings (note- a.02)	121,444	121,110
Revaluation Reserve (note- a.03)	753,343	636,826
Dividend Equalisation Fund	2,955	2,955
<b>Total Equity</b>	<b>1,095,751</b>	<b>959,081</b>

**a.01 , Paid-up capital:**

Type of Share	No. of Shares	Face value	Issu Date	Figure in Taka"000"	
Ordinary Share	6,000	10.00	10/11/1997	60,000	60,000
Bonus Share	600	10.00	23/04/2005	6,000	6,000
Bonus Share	990	10.00	26/01/2010	9,900	9,900
Bonus Share	1,214	10.00	08/02/2012	12,140	12,140
Bonus Share	1,584	10.00	24/01/2013	15,844	15,844
Bonus Share	3,117	10.00	26/01/2014	31,170	31,170
Bonus Share	1,351	10.00	07/01/2015	13,510	13,510
Bonus Share	1,486	10.00	26/12/2016	14,860	14,860
Bonus Share	1,634	10.00	28/12/2017	16,340	16,340
Bonus Share	899	10.00	05/01/2020	8,988	8,988
Bonus Share	944	10.00	09/01/2023	9,438	9,438
Bonus Share	1,982	10.00	15/01/2024	19,819	-
<b>Total: 21,800,897 shares @ Tk. 10.00 each</b>				<b>218,009</b>	<b>198,190</b>

**a.02 , Retained Earnings**

Opening Balance	121,110	140,203
Less: Dividend Paid	-	9,438
Less: Transfer to Share Capital	19,819	9,438
Add: Prior year adjustment of Investment of Associate	-	76
Less: Prior Year Adjustment	-	978
	101,291	120,425
Add: Total Comprehensive Income for the year	20,153	721
	121,444	121,146
Less: Transferred to Dividend Equalisation Fund	-	36
Retained Earnings	<b>121,444</b>	<b>121,110</b>

As at March, 31 2024
----------------------------

As at June, 30 2023
---------------------------

Figure in Taka"000"

**a.03, Revaluation Reserve**

Opening Balance	636,826	636,826
Add: Revaluation gain of land	124,099	-
Less: Transferred to Deferred tax Liabilities (note 14.01)	7,582	-
	<b>753,343</b>	<b>636,826</b>

**b) Net Asset Value Per Share (NAV)**

Total Assets	1,226,769	1,089,931
Less Total liabilities :	131,018	130,850
Non Current Liabilities	67,943	62,121
Current Liabilities	63,075	68,729
Net Assets:	<b>1,095,751</b>	<b>959,081</b>
Number of outstanding shares at the year end	21,801	21,801
Net Asset Value Per Share (NAV)	<b>50.26</b>	<b>43.99</b>

**c) Basic and diluted Earnings Per Share:****Basic Earning Per Share:**

Profit Attributable to ordinary shareholders	20,153	8,721
Number of outstanding shares at the year end	21,801	21,801
Basic Earning per Share (EPS)	<b>0.92</b>	<b>0.40</b>

March, 31 2024
-------------------

March, 31 2023
-------------------

Figure in Taka"000"

**Diluted Earning Per Share:**

Diluted EPS is determined by adjusting the Profit or loss attributable to ordinary shareholders and the weighted average number of ordinary shares outstanding, for the effects of all dilutive potential ordinary shares. However, dilution of EPS is not applicable for these financial statements as there was no potential dilutive ordinary share during the relevant period.

**d) Net operating cash flows per share (NOCFPS)**

Net Cash from Operating Activities	50,965	38,624
Number of outstanding shares at the year end	21,801	21,801
Net operating cash flows per share (NOCFPS)	<b>2.34</b>	<b>1.77</b>

**e) Reconciliation of Net profit with Cash Flows from Operating Activities**

For the third quarter ended March 31, 2024

Particulars	March, 31 2024	March, 31 2023
	Figure in Taka"000"	
Profit Before Tax	25,644	11,189
Depreciation	18,529	18,608
Bad debt	1,546	272
(Gain) / Loss on Disposal	-	-
FDR Interest	(1,205)	(1,699)
Bank Interest	(342)	(223)
Investment Income (Share of (Profit) /Loss of Associate)	(29)	(45)
Financial Charges	2,756	3,627
Payment for lease	(1,361)	(1,361)
(Increase)/Decrease in Inventories	(257)	(234)
(Increase)/Decrease in Trade and other receivable	689	840
(Increase)/Decrease in Advance, Deposits & Prepayment	4,498	2,617
Increase/(Decrease) in Trade Payable	(2,337)	5,235
Increase/(Decrease) in other Payable	1,153	1,376
Increase/(Decrease) in Provision & accruals	2,496	586
Increase/(Decrease) in WPPF	1,282	559
Cash Flows from operation	53,062	41,349
Tax Paid	(2,097)	(2,725)
	50,965	38,624

**32. Related Party Disclosures (IAS-24):**

as on 31st March 2024 ( Figure in Taka "000")

SL.No	Particulars	Nature of Relation	Basis of transactions	Total Transaction Value	Outstanding
1.00	Nurse Hostel	Mrs. Latifa Haroon, W/O Dr.A B M Haroon	Space rent as per contract	1,361	-
2.00	The Imaging Services Ltd.	Associate company	Space rent as per contract		180
3.00	Purabi General Insurance Company Limited	Common director	Insurance Premium as per contract	248	-
4.00	M.H. Samorita Hospital & Medical College	Common director	Pathology Test as per negotiation	1,270	958

March, 31 2024	June, 30 2023
Figure in Taka"000"	

**33. Disclosure of key management personnel compensation:**

Detailed disclosure regarding the compensation packages of key management personnel is presented below.

Key management are those persons having authority and responsibility for planing, Directing and controlling the activities of the company.

i) Remuneration and Meeting fees for Non-excutive directors


Remuneration & Other benefits	-	-
Board meeting fees	366	440
	366	440


ii) Compensation of key management personnel

a) Short-term employee benefits	12,428	17,078
b) Post-employment benefits	-	-
c) Other long-term benefits	-	-
d) Termination benefits	-	-
e) Share-based payment	-	-
	12,428	17,078


Short term employee benefits consisted of salary, bonus, medical allowance, housing, cars, fees or subsidized goods or services for key management personnel.

Key management personel includes Managing Director, Company Secretary, Chief Financial Officer, Head of Internal Audit and Compliance, Head of Administration and Human Resources and Chief Medical Officer.

  
C F O

  
Company Secretary

  
Managing Director

  
Director

  
Chairman